RGNX Earnings Date: Nov 5, 2026 (Estimated) — REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RGNX's next earnings date?
REGENXBIO Inc. (RGNX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.30 on revenue of $14.9M.
How did RGNX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), REGENXBIO Inc. posted EPS of $0.43 versus the $0.08 estimate, a beat of 258.3%. Revenue was $108.0M against a $97.6M estimate. The stock's 1-day post-earnings move was +7.4%.
How much does RGNX stock move after earnings?
RGNX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.5% (up or down) in the day after earnings.
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.08 | 0.43 | +258.33% | $108.0M | ✅ Beat | +7.43% | +3.90% | -12.38% |
| 2026-05-14 | Q1 2026 | -1.40 | -1.72 | -22.86% | $6.4M | ❌ Miss | -37.80% | -40.54% | -33.67% |
| 2026-03-05 | Q4 2025 | -0.91 | -1.30 | -42.86% | $30.3M | ❌ Miss | -4.60% | +2.63% | -6.67% |
| 2025-11-06 | Q3 2025 | -1.33 | -1.20 | +9.77% | $29.7M | ✅ Beat | -3.79% | -0.09% | +13.35% |
| 2025-08-07 | Q2 2025 | -1.08 | -1.38 | -27.78% | $21.4M | ❌ Miss | -4.01% | +8.51% | +17.98% |
| 2025-03-13 | Q4 2024 | -1.08 | -1.01 | +6.48% | $21.2M | ✅ Beat | +2.60% | +27.63% | -10.08% |
| 2024-08-01 | Q2 2024 | -1.29 | -1.05 | +18.60% | $22.3M | ✅ Beat | -2.03% | -10.67% | -8.19% |
| 2024-05-08 | Q1 2024 | -1.26 | -1.38 | -9.52% | $15.6M | ❌ Miss | -5.94% | -2.64% | -15.54% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $108.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License and Service | 96.1% | $103.8M | +462.4% | $21.2M | $87.0M | $18.5M | $23.6M |
| Service | 3.9% | $4.2M | +44.4% | — | $2.0M | $2.9M | $6.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.